Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations

AIDS

Volumn 20, Issue 14, 2006, Pages 1891-1892

  Blanco, Jose Luis ^a   Biglia, Alejandra ^a   Lazzari, Elisa De ^a   Mallolas, Josep ^a   Martinez, Esteban ^a   Pumarola, Tomás ^a   Larrousse, María ^a   Milinkovic, Ana ^a   León, Agathe ^a   Lonca, Montserrat ^a   Laguno, Montserrat ^a   Gatell, Josep María ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; THYMIDINE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; VIRUS LOAD;

DIDANOSINE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NUCLEOSIDES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; THYMIDINE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33748509939     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000244210.33876.26     Document Type: Article

References (6)

1. Jonson VA, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1. HIV Topics Med 2005; 13:51-57.
2. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997; 41:757-762.
3. Molina JM, Marcelin AG, Pavie J, Heripret L, De Boever CM, Troccaz M, et al. Didanosine in HIV-1 infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. JID 2005; 191:840-847.
4. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, ramdomized, double-blind study. AIDS 2002; 16:1257-1263.
5. Blanco JL, Biglia A, Arnedo M, Martínez E, Mallolas J, Milinkovic A, et al. Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor (PI). AIDS 2005; 19:829-831.
6. Marcelin A-G, Flandre P, Pavie J, Schmidely N, Wirden M, Lada O, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49:1739-1744.